Multi-scale integrative analyses identify THBS2 + cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma

Quick Facts

  • Publication title: Multi-scale integrative analyses identify THBS2 + cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma
  • Journal: Theranostics
  • Year: 2022
  • DOI: 10.7150/thno.69590
  • PMID/PMCID: 35547750; PMC9065207

Research overview

Results: We identified and validated THBS2, at multi-omic levels, as a tumor size-independent biomarker that robustly predicted post-surgical survival in multiple independent clinical cohorts of early-stage LUAD. However, biomarkers stratifying this high-risk subset and molecular underpinnings underlying the aggressive phenotype remain unclear.

Key findings

Rationale: Subsets of patients with early-stage lung adenocarcinoma (LUAD) have a poor post-surgical course after curative surgery.

However, biomarkers stratifying this high-risk subset and molecular underpinnings underlying the aggressive phenotype remain unclear.

Methods: We integrated bulk and single-cell transcriptomics, proteomics, secretome and spatial profiling of clinical early-stage LUAD samples to identify molecular underpinnings that promote the aggressive phenotype.

Results: We identified and validated THBS2, at multi-omic levels, as a tumor size-independent biomarker that robustly predicted post-surgical survival in multiple independent clinical cohorts of early-stage LUAD.

Echo Biotech Role

Echo Biotech contributed EV isolation and purification; the study also used or cited Exosupur®.

Related platforms: Exoomics®, Research Reagents & Tools

Related services and capabilities: EV Isolation & Purification, Research Reagent / Product Supply

Related products or reagents: Exosupur® EV Isolation/Purification Kit

References

Original publication: Multi-scale integrative analyses identify THBS2 + cancer-associated fibroblasts as a key orchestrator promoting aggressiveness in early-stage lung adenocarcinoma Theranostics. 2022. DOI: 10.7150/thno.69590. PMID/PMCID: 35547750; PMC9065207.